Bisphosphonates prevent periprosthetic bone loss following arthroplasty over the mid-term .
Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials
Osteoporos Int. 2012 Jun;23(6):1823-34. doi: 10.1007/s00198-011-1797-5. Epub 2011 Sep 20A meta-analysis consisting of 14 RCTs (671 patients) was conducted to determine the efficacy of bisphosphonates (BPs) on maintaining periprosthetic bone mass after joint arthroplasty, as well as their potential influential factors and adverse events. After 72 months of follow up, bisphosphonates demonstrated significant short-term and middle-term efficacy in bone loss prevention, with second and third generation of BPs being most effective with no adverse side effects.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
